SecBot SecBot

TRAW drug pipeline

Traws Pharma, Inc. · 4 rated drugs
$0.2500
−10.7% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±10.0%
1-day, median of 7 events
IV rank
No data
No current options data
Rated drugs
4
3 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketUnknown — Phase 2a is complete but no Phase 3 trial has been announced. If Phase 3 starts in 2026-2027, potential FDA submission would be at least 2-3 years away.

ratutrelvir Updated Jul 10

What to watch

Ratutrelvir's Phase 2 data (completed Feb 2026) showed a differentiated safety profile vs Paxlovid, but the company has not yet outlined a path to Phase 3 or given a timeline. Meanwhile, Traws Pharma's other drug (tivoxavir marboxil) has an FDA clinical hold and both covering analysts downgraded TRAW to Neutral in June 2026. Watch for a Phase 3 announcement or FDA meeting readout as the next potential catalyst; without one, ratutrelvir is a long-odds development-stage asset at a cash-strapped micro-cap.

Bull case
  • Phase 2 data showed ratutrelvir had a differentiated profile vs Paxlovid: fewer treatment-related adverse events, no viral rebounds (vs 8.3% with Paxlovid), and equivalent time to symptom resolution (source: GlobeNewswire Feb 19, 2026 via BioSpace).
  • Ratutrelvir does not require ritonavir boosting, targeting the ~30% of COVID patients who are Paxlovid-ineligible due to drug-drug interactions, a large underserved population (source: BioSpace press release).
  • Phase 1 PK data showed ratutrelvir maintained plasma concentrations ~13x above EC50 with once-daily 600mg dosing for 10 days, suggesting a robust antiviral profile (source: BioSpace / Nasdaq press release).
Bear case
  • No Phase 3 trial has been announced, and the company has not stated a timeline for further development of ratutrelvir, making the path to market highly uncertain (source: Traws Pharma corporate updates).
  • The COVID oral antiviral market is already crowded with Pfizer's Paxlovid (nirmatrelvir/ritonavir) and Shionogi's ensitrelvir (Xocova), which received FDA approval for post-exposure prophylaxis, raising the competitive bar for a new entrant (source: The Lancet Infectious Diseases / CIDRAP).
  • Traws Pharma had only ~$3.1M in cash as of March 31, 2026, with a going-concern warning in its 10-K; even with a $60M PIPE facility, the company is funding operations only into Q1 2027, raising doubt about its ability to finance a Phase 3 trial (source: BioSpace Q1 2026 earnings / StockTitan).
▼ bearish
Impact
PhasePhase 2 (RDEB-SCC); previously Phase 3 (MDS, failed)
Time to marketUnknown — the drug has failed Phase 3 in MDS and is being repositioned for RDEB-SCC. A confirmatory Phase 2 trial is being planned but requires a partner. Best case 4-7 years from a partnership deal to potential approval in this ultra-rare indication.

rigosertib Updated Jul 10

What to watch

Rigosertib is not the primary value driver at Traws Pharma, the company's antiviral pipeline (tivoxavir) and recent hantavirus/Ebola programs have been the key stock movers in 2026. Watch for a potential rigosertib partnership/licensing deal, but the stock's trajectory is being set by the antiviral clinical holds and regulatory setbacks, not this oncology program.

Bull case
  • Published data in British Journal of Dermatology (June 2025) showed an 80% overall response rate and 50% complete response rate in RDEB-SCC, an ultra-rare condition with no approved therapies, this suggests a legitimate signal in an orphan population where smaller trials might support registration.
  • If Traws Pharma secures a partnership deal, the partner could fund a confirmatory trial, potentially unlocking a regulatory path. The RDEB-SCC indication has high unmet need and could qualify for accelerated approval pathways like Breakthrough Therapy designation.
  • Rigosertib has issued composition-of-matter patents and method-of-treatment patents extending to 2037-2042, providing long exclusivity runway if approved.
Bear case
  • Rigosertib has twice failed Phase 3 trials (ONTIME 2014, INSPIRE 2020) in MDS, failing to improve survival vs. physician's choice, a significant development setback that raises questions about the drug's overall clinical profile.
  • The RDEB-SCC data is based on just 5 evaluable patients, extremely preliminary. Even the published paper's authors note this is a first-in-disease trial, and a confirmatory Phase 2 hasn't even started enrolling.
  • Traws Pharma has explicitly deprioritized rigosertib, describing it as a 'legacy oncology program' and is actively seeking a partner. The company's focus and cash are on antivirals, not cancer.
▼ bearish
Impact
PhasePhase 1 completed
Time to marketUnknown; several years away at minimum. The program is stalled at Phase 1 with clinical holds in both the US and UK, and the company is developing backup compounds to address mutagenicity concerns.

tivoxavir marboxil Updated Jul 10

What to watch

Avoid TRAW until there is a clear path to resolving the FDA clinical hold AND the UK regulatory impasse. The stock has already fallen ~77% from its 52-week high of $3.27 to ~$0.76. The company has only ~$5M cash (runway into Q1 2027), a going-concern qualification, and a $139M shelf overhang, any positive catalyst is years away, while near-term dilution risk is acute.

Bull case
  • Phase 1 data showed a single dose maintained plasma drug levels above the EC90 for >23 days, suggesting potential for best-in-class once-monthly prophylaxis vs. Xofluza's single-dose treatment profile (source: PRNewswire, Dec 2024 / Jan 2025).
  • Preclinical data showed potent inhibition of drug-resistant influenza strains and H5N1 bird flu in multiple animal models including ferrets and non-human primates (source: GlobeNewswire, Mar 2025).
  • The IND filing with FDA was the final step for formal BARDA consideration for the US strategic stockpile, a potential non-dilutive funding source if clinical hold is resolved (source: BioSpace, Jan 2026).
Bear case
  • FDA placed the IND on clinical hold in February 2026 due to mutagenicity data concerns, drug cannot be tested in US until resolved, with no timeline for resolution (source: Investing.com, Feb 2026; SEC 424B5 filing, Jul 2026).
  • UK MHRA issued a negative review of the planned Phase 2a human influenza challenge study in June 2026, forcing deferral of the entire program, a second major regulatory roadblock (source: FierceBiotech, Jun 2026).
  • Traws Pharma is severely financially distressed: ~$5M cash, going-concern qualification, $647M accumulated deficit, and a $139M shelf registration (10.7x the ~$10M market cap) creating massive dilution overhang (source: SEC 424B5 prospectus, Jul 10, 2026).
▼ bearish
Impact
PhasePhase 2
Time to marketUnknown — the Phase 2a study is closed to accrual, the company is seeking a partner to continue development. If partnered, earliest potential approval would likely be 3-5+ years away.

narazaciclib Updated Jul 10

What to watch

Narazaciclib is a non-core, legacy asset at Traws Pharma. The company's stock is driven entirely by its antiviral pipeline (tivoxavir marboxil for influenza, ratutrelvir for COVID-19), not by narazaciclib. Investors should not buy TRAW for this drug. Any partnership deal for narazaciclib would be a modest positive surprise but is unlikely to move the stock significantly given the company's ~$10M market cap and focus on antivirals.

Bull case
  • Differentiated multi-kinase profile (CDK4/6 + CSF1R + ARK5) may overcome resistance to existing CDK4/6 inhibitors and reduce neutropenia, preclinical data comparing favorably to palbociclib.
  • Phase 1 dose escalation completed successfully with an established RP2D, and the mechanism of action in LGEEC is validated by Phase 2 data from approved CDK4/6 inhibitors.
  • If Traws secures a licensing or partnership deal for narazaciclib, it could provide non-dilutive funding and validate the asset's value, the company is actively seeking partners.
Bear case
  • Narazaciclib is a non-core legacy asset, Traws Pharma has pivoted to antivirals (influenza/COVID) and explicitly lists narazaciclib for partnering, not self-development.
  • Intense competition from three blockbuster FDA-approved CDK4/6 inhibitors (Pfizer's Ibrance/palbociclib, Novartis' Kisqali/ribociclib, Lilly's Verzenio/abemaciclib) that already dominate the market.
  • No hard, dated catalyst for narazaciclib exists, the Phase 1/2 study is closed with no disclosed plans for company-sponsored Phase 2b/3 trials.

Past FDA events & how the stock moved

7 events
DateDrugEvent1 day5 days
Jun 30, 2026tivoxavir marboxilNDA filed−1.2%−19.5%
Jun 12, 2026tivoxavir marboxilClinical hold−40.2%−29.9%
May 27, 2026tivoxavir marboxilClinical hold−3.8%−8.2%
May 15, 2026tivoxavir marboxilClinical hold+8.0%−8.6%
Apr 15, 2026tivoxavir marboxilClinical hold−23.9%−18.9%
Mar 16, 2026tivoxavir marboxilClinical hold+10.0%+11.0%
Feb 19, 2026tivoxavir marboxilClinical hold−18.3%−17.8%